CBLIF

Across TCGA pan-cancer cohorts, CBLIF Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CBLIF data layer compared with 22 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher CBLIF Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CBLIF expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

OV, COAD, and SCLC are the cancer types where CBLIF Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	All	0.064	0.541	<.001	18	view →
COAD	OS	Median	All	0.054	0.871	<.001	18	view →
SCLC	OS	Median	III,IV	0.082	0.639	<.001	12	view →
PRAD	DFS	Median	All	0.435	0.888	<.001	6	view →
SKCM	OS	Median	II,III,IV	0.945	0.722	.020	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CBLIF–OV (DFS)

Open the OV breakdown →